How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
Journal article
Matthew M.Y. Lee, Mark C. Petrie, John McMurray and Naveed Sattar. (2020). How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Arteriosclerosis Thrombosis and Vascular Biology. 40(3), pp. 506-522. https://doi.org/10.1161/ATVBAHA.119.311904
Authors | Matthew M.Y. Lee, Mark C. Petrie, John McMurray and Naveed Sattar |
---|---|
Abstract | Objective: Approach and Results: Conclusions: |
Keywords | humans; clinical trials; sodium glucose cotransporter 2; cardiovascular diseases; glucagon-like peptide-1 receptor agonists |
Year | 2020 |
Journal | Arteriosclerosis Thrombosis and Vascular Biology |
Journal citation | 40 (3), pp. 506-522 |
Publisher | Lippincott Williams & Wilkins |
ISSN | 1079-5642 |
Digital Object Identifier (DOI) | https://doi.org/10.1161/ATVBAHA.119.311904 |
Scopus EID | 2-s2.0-85081165799 |
Publisher's version | File Access Level Controlled |
Publication process dates | |
Deposited | 28 Apr 2021 |
https://acuresearchbank.acu.edu.au/item/8vy7v/how-do-sglt2-sodium-glucose-cotransporter-2-inhibitors-and-glp-1-glucagon-like-peptide-1-receptor-agonists-reduce-cardiovascular-outcomes
Restricted files
Publisher's version
1680
total views0
total downloads0
views this month0
downloads this month